Minireview: Constitutively Active G Protein-Coupled Receptors: Potential Mechanisms of Receptor Activation

References

• Khorana H. G. Rhodopsin, photoreceptor of the rod cell. J. Biol. Chem. 1992; 267: 1–4
   PubMed Web of Science ®Google Scholar
• Savarese T. M., Fraser C. M. In vitro mutagenesis and the search for structure function relationships among G protein-coupled receptors. Biochem. J. 1992; 283: 1–19
   PubMed Web of Science ®Google Scholar
• Cotecchia S., Exum S., Caron M. G., Lefkowitz R. J. Regions of α1-adrenergic receptor involved in coupling to phosphatidyl-inositol hydrolysis and enhanced sensivity of biological function. Proc. Natl. Acad. Sci. USA 1990; 87: 2896–2900
   PubMed Web of Science ®Google Scholar
• Kjelsberg M. A., Cotecchia S., Ostrowski J., Caron M. G., Lefkowitz R. J. Constitutive activation of the α1B-adrenergic receptor by all amino acid substitution at a single site. J. Biol. Chem. 1992; 267: 1430–1433
   PubMed Web of Science ®Google Scholar
• Samama P., Cotecchia S., Costa T., Lefkowitz R. J. A mutation-induced activated state of the β2-adrenergic receptor: extending the ternary complex model. J. Biol. Chem. 1993; 268: 4625–4636
   PubMed Web of Science ®Google Scholar
• Ren Q., Kurose H., Lefkowitz R. J., Cotecchia S. Constitutively active mutants of the α2A-adrenergic receptor. J. Biol. Chem. 1993; 268: 16483–16487
   PubMed Web of Science ®Google Scholar
• Högger P., Shockley M. S., Lameh J., Sadee W. Activating mutations in N- and C-terminal 13 loop junctions of muscarinic acetylcholine Hm1 receptors. J. Biol. Chem. 1995; 270: 7405–7410
   PubMed Web of Science ®Google Scholar
• Boone C., Davis N. G., Sprague G. F., Jr. Mutations that alter the third cytoplasmatic loop of the a-factor receptor lead to constitutive and hypersensitive phenotype. Proc. Natl. Acad. Sci. USA 1993; 90: 9921–9258
   PubMed Web of Science ®Google Scholar
• Blüml K., Mutschler E., Wess J. Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. J. Biol. Chem. 1994; 269: 18870–18876
   PubMed Web of Science ®Google Scholar
• Spalding T. A., Burstein E. S., Brauner-Osbourne H., Hill-Eubanks D., Brann M. R. Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis. J. Pharmacol. Exp. Ther. 1996; 275: 1274–1279
   Web of Science ®Google Scholar
• Nanevicz T., Wang L., Chen M., Ishii M., Coughlin S. R. Thrombin receptor activating mutations. J. Biol. Chem. 1996; 271: 702–706
   PubMed Web of Science ®Google Scholar
• Burstein E. S., Spalding T. A., Brann M. R. Constitutive activation of chimeric m2/m5 muscarinic receptors and dileneation of G-protein coupling selectivity domains. Biochem. Pharmacol. 1996; 51: 539–544
   PubMed Web of Science ®Google Scholar
• Perez D. M., Hwa J., Gaivin R., Mathur M., Brown F., Graham R. M. Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. Mol. Pharmacol. 1996; 49: 112–122
   PubMed Web of Science ®Google Scholar
• Robinson P. R., Cohen G. B., Zhukovsky E. A., Oprian D. D. Constitutively active mutants of rhodopsin. Neuron 1992; 9: 719–725
   PubMed Web of Science ®Google Scholar
• Rao V. R., Cohen G. B., Oprian D. D. Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness. Nature 1994; 367: 639–642
   PubMed Web of Science ®Google Scholar
• Dryga T. P., Berson E. L., Rao V. R., Oprian D. D. Heterozygous missence mutation in the rhodopsin gene as a cause of congenital stationary night blindness. Nature Genet. 1993; 4: 280–283
   PubMed Web of Science ®Google Scholar
• Shenker A., Laue L., Kosugi S., Merenddino J. J., Jr, Minegishi T., Cutler G. B., Jr. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993; 365: 652–654
   PubMed Web of Science ®Google Scholar
• Kosugi S., Van Dop C., Geffner M. E., Rabl W., Carel J. C., Chaussain J. L., Mori T., Merendino J. J., Jr, Shenker A. Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty. Hum. Mol. Genet. 1995; 4: 183–188
   PubMed Web of Science ®Google Scholar
• Parma J., Duprez L., Van Sande J., Cochaux P., Gervy C., Mockel J., Dumont J., Vassart G. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993; 365: 649–651
   PubMed Web of Science ®Google Scholar
• Parma J., Van Sande J., Swillens S., Tonacchera M., Dumont J., Vassart G. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyper-functioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades. Mol. Endocrinol. 1995; 9: 725–733
   PubMedGoogle Scholar
• Duprez L., Parma J., Van Sande J., Allgeier A., Leclère J., Schvartz C., Delisle M.-J., Decoulx M., Orgiazzi J., Dumont J., Vassart G. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nature Genet. 1994; 7: 396–401
   PubMed Web of Science ®Google Scholar
• Paschke R., Tonacchera M., Van Sande J., Parma J., Vassart G. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. J. Clin. Endocrinol. Meta. 1994; 79: 1785–1789
   PubMed Web of Science ®Google Scholar
• Robbins L. S., Nadeau J. H., Johnson K. R., Kelly M. A., Roselli-Rehfuss L., Baack E., Mountjoy K. G., Cone R. D. Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell 1993; 72: 827–34
   PubMed Web of Science ®Google Scholar
• Schipani E., Kruse K., Jüppner H. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 1995; 268: 98–100
   PubMed Web of Science ®Google Scholar
• Del Castillo J., Katz B. Interaction at end-plate receptors between different choline derivates. Proc. R. Soc. Lond. B. Biol. Sci. 1957; 146: 369–381
   PubMed Web of Science ®Google Scholar
• DeLean A., Stadel J. M., Lefkowitz R. J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J. Biol. Chem. 1980; 268: 4625–4636
   Google Scholar
• Tiberi M., Caron M. High agonist-independent activity is a distinguishing feature of the dopamine DIB receptor subtype. J. Biol. Chem. 1994; 269: 27295–27931
   Web of Science ®Google Scholar
• Cetani F., Tonacchera M., Vassart G. Differential effects of NaCl concentration on the constitutive activity of the thyrotropin and the luteinizing hormone/chorionic gonadotropin receptors. FEBS Lett. 1996; 378: 27–31
   PubMed Web of Science ®Google Scholar
• Costa T., Ogino Y., Munson P. J., Onaran H. O., Rodbard D. Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol. Pharmacol. 1992; 41: 549–560
   PubMed Web of Science ®Google Scholar
• Schütz W., Freissmuth M. Reverse intrinsic activity of antagonists on G protein-coupled receptors. Trends Pharmacol. Sci. 1992; 13: 376–380
   PubMed Web of Science ®Google Scholar
• Milligan G., Bond R. A., Lee M. Inverse agonism: pharmacological curiosity or potential therapeutic strategy?. Trends Pharmacol. Sci. 1995; 16: 10–13
   PubMed Web of Science ®Google Scholar
• Chidiac P., Hebert T. E., Valiquette M., Dennis M., Bouvier M. Inverse agonist activity of β-adrenergic antagonists. Mol. Pharmacol. 1994; 45: 490–499
   PubMed Web of Science ®Google Scholar
• Samama P., Pei G., Costa T., Coteccha S., Lefkowitz R. J. Negative Antagonists promote an inactive conformation of the β2-adrenergic receptor. Mol. Pharmacol. 1994; 45: 390–394
   PubMed Web of Science ®Google Scholar
• Barker E. L., Westphal R. S., Schmidt D., Sanders-Bush E. Constitutively active 5-hydroxytryptamine2c receptor reveal novel inverse agonist activity of receptor ligands. J. Biol. Chem. 1994; 269: 11687–11690
   PubMed Web of Science ®Google Scholar
• Leeb-Lundberg L. M. F., Mathis S. A., Herzig M. C. S. Antagonists of Bradykinin that stabilize a G-protein-uncoupled state of the B2 receptor act as inverse agonists in rat myometrial cells. J. Biol. Chem. 1994; 269: 25970–25973
   PubMed Web of Science ®Google Scholar
• Cohen G. B., Oprian D. D., Robinson P. R. Mechanism of activation and inactivation of opsin: role of Glu113 and Lys296. Biochemistry 1992; 31: 12592–12601
   PubMed Web of Science ®Google Scholar
• Arnis S., Fahmy K., Hofmann K. P., Sakmar T. P. A conserved carboxylic acid group mediates light-dependent proton uptake and signaling by rhodopsin. J. Biol. Chem. 1994; 269: 23879–23881
   PubMed Web of Science ®Google Scholar
• Farahbakhsh Z. T., Ridge K. D., Khorana H. G., Hubbell W. L. Mapping light-dependent structural changes in the cyto-plasmatic loop connecting helices C and D in rhodopsin: a site directed spin labeling study. Biochemistry 1995; 34: 8812–8819
   PubMed Web of Science ®Google Scholar
• Cohen G. B., Yang T., Robinson P. R., Oprian D. D. Constitutive activation of opsin: influence of charge at position 134 and size at position 296. Biochemistry 1993; 32: 6111–6115
   PubMed Web of Science ®Google Scholar
• Sakmar T. P., Franke R. R., Khorana H. G. Glutamic acid-113 serves as the retinylidene Schiff base counterion in bovine rhodopsin. Proc. Natl. Acad. Sci. USA 1989; 86: 8309–8313
   PubMed Web of Science ®Google Scholar
• Franke R. R., König B., Sakmar T. P., Khorana H. G., Hofmann K. P. Rhodopsin mutants that bind but fail to activate transducin. Science 1990; 250: 132–125
   PubMed Web of Science ®Google Scholar
• Scheer A., Fanelli F., Costa T., De Benedetti P. G., Cotecchia S. Constitutively active mutants of the α1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation. EMBO J.
   Google Scholar
• Trumpp-Kallmeyer S., Hoflack J., Bruinvels A., Hibert M. Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. J. Med. Chem. 1992; 35: 3448–3462
   PubMed Web of Science ®Google Scholar
• Oliveira L., Paiva A. C. M., Sander C., Vriend G. A common step for signal transduction in G protein-coupled receptors. Trends Pharmacol. Sci. 1994; 15: 170–172
   PubMed Web of Science ®Google Scholar
• Fanelli F., Menziani M. C, De Benedetti P. G. Computer simulations of signal transduction mechanism in α1B-adrenergic and m3-muscarinic receptors. Protein Eng., 8: 557–564
   PubMedGoogle Scholar
• Baldwin J. M. The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 1993; 12: 1693–1703
   PubMed Web of Science ®Google Scholar